Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Sponsor
CHEOL WHAN LEE, M.D., Ph.D
Study ID
NCT03208465
Phase
PHASE4
Status
Completed

Conditions

  • Coronary Disease
  • Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin — DRUG
    In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
  • Sitagliptin — DRUG
    In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.

Study Details

This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.

Key Dates

Start date
Aug 7, 2017
Status verified
Aug 2019
Primary completion
Aug 1, 2019
Completion
Aug 1, 2019

Study Design

Enrollment
100 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Patients with Empagliflozin
  • Active Comparator: Patients with Sitagliptin

Primary Outcome Measure

Percent change in global myocardial perfusion reserve (MPR) index [ Time Frame: 6 months ]

Related Studies